Shanghai Pharmaceuticals Holdings ADR (SHPMY) – tečaj delnic in novice

Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia

Vizitka: Shanghai Pharmaceuticals Holdings ADR

Generalni direktor-

Št. zaposlenih48,6 tis.

Ustanovljeno18. jan. 1994

Sedež-

Sektor-

Spletno mestosphchina.com

Vse vrednosti v valuti CNY	sep. 2025	dec. 2025	mar. 2026	jun. 2026
Prihodek	73,48 mrd.	68,51 mrd.	75,26 mrd.	72,21 mrd.
Strošek prodanega blaga	66,03 mrd.	60,55 mrd.	67,17 mrd.	64,09 mrd.
Stroški materiala in storitev	66,03 mrd.	60,55 mrd.	67,17 mrd.	64,09 mrd.
Stroški raziskav in razvoja	556,53 mio.	824,53 mio.	468,22 mio.	502,64 mio.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	4,70 mrd.	4,97 mrd.	4,59 mrd.	4,65 mrd.
Operativni strošek	5,58 mrd.	5,91 mrd.	5,47 mrd.	5,55 mrd.
Skupni operativni stroški	71,60 mrd.	66,47 mrd.	72,63 mrd.	69,64 mrd.
Prihodek iz poslovanja	1,88 mrd.	2,04 mrd.	2,63 mrd.	2,57 mrd.
Drug prihodek, ki ne izhaja iz poslovanja	−84,84 mio.	−63,65 mio.	−47,88 mio.	−7,43 mio.
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	1,48 mrd.	1,52 mrd.	2,42 mrd.	3,21 mrd.
Zaslužek pred obdavčitvijo brez izrednih postavk	1,61 mrd.	1,44 mrd.	2,27 mrd.	3,03 mrd.
Odhodek iz obdavčitve dobička	485,91 mio.	534,14 mio.	569,09 mio.	720,64 mio.
Dejanska davčna stopnja	32,89 %	35,10 %	23,52 %	22,43 %
Drugi operativni stroški	129,62 mio.	271,29 mio.	132,16 mio.	186,62 mio.
Čisti prihodek	688,20 mio.	577,49 mio.	1,42 mrd.	2,09 mrd.
Neto stopnja dobička	0,94 %	0,84 %	1,88 %	2,89 %
Čisti dobiček na delnico	-	-	-	-
Prihodki iz obresti in naložb	206,57 mio.	-	38,70 mio.	873,52 mio.
Obrestni odhodki	−393,02 mio.	−470,36 mio.	−347,64 mio.	−358,39 mio.
Neto obrestni odhodki	−186,45 mio.	−470,36 mio.	−308,94 mio.	515,13 mio.
Stroški amortizacije	-	-	-	-
EBITDA	2,26 mrd.	2,54 mrd.	3,12 mrd.	3,07 mrd.
Dobiček ali izguba pri prodaji sredstev	39,99 mio.	−157,15 mio.	-	−179,70 mio.

Finance

Vprašajte kar koli